Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.

Literature DB >> 19959752

Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.

Mingzhao Xing.

Abstract

Entities: Disease

Mesh：

Year: 2009 PMID： 19959752 PMCID： PMC2795651 DOI： 10.1210/jc.2009-2147

Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958

× No keyword cloud information.

22 in total

1. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma".

Authors: M L Carcangiu; G Zampi; J Rosai
Journal: Am J Surg Pathol Date: 1984-09 Impact factor: 6.394

Review 2. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors: Yuri E Nikiforov
Journal: Endocr Pathol Date: 2004 Impact factor: 3.943

Review 3. BRAF mutation in thyroid cancer.

Authors: M Xing
Journal: Endocr Relat Cancer Date: 2005-06 Impact factor: 5.678

4. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.

Authors: F Basolo; F Pisaturo; L E Pollina; G Fontanini; R Elisei; E Molinaro; P Iacconi; P Miccoli; F Pacini
Journal: Thyroid Date: 2000-01 Impact factor: 6.568

5. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors: Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal: Am J Clin Pathol Date: 2003-07 Impact factor: 2.493

6. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.

Authors: Marco Volante; Ida Rapa; Manoj Gandhi; Gianni Bussolati; Daniela Giachino; Mauro Papotti; Yuri E Nikiforov
Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958

7. Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

Authors: V Vasko; M Ferrand; J Di Cristofaro; P Carayon; J F Henry; C de Micco
Journal: J Clin Endocrinol Metab Date: 2003-06 Impact factor: 5.958

8. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

Authors: Ginesa Garcia-Rostan; Hongyu Zhao; Robert L Camp; Marina Pollan; Agustin Herrero; Javier Pardo; Ran Wu; Maria Luisa Carcangiu; Jose Costa; Giovanni Tallini
Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544

9. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas.

Authors: G Manenti; S Pilotti; F C Re; G Della Porta; M A Pierotti
Journal: Eur J Cancer Date: 1994 Impact factor: 9.162

10. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.

Authors: A Sakamoto; N Kasai; H Sugano
Journal: Cancer Date: 1983-11-15 Impact factor: 6.860

5 in total

1. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Authors: Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing
Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958